These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27063447)

  • 1. Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actions.
    Chakraborty S; Kumar A; Butt NA; Zhang L; Williams R; Rimando AM; Biswas PK; Levenson AS
    Mol Biosyst; 2016 May; 12(5):1702-9. PubMed ID: 27063447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor.
    Lundqvist J; Tringali C; Oskarsson A
    J Steroid Biochem Mol Biol; 2017 Nov; 174():161-168. PubMed ID: 28888979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells.
    Wang TT; Schoene NW; Kim YS; Mizuno CS; Rimando AM
    Mol Nutr Food Res; 2010 Mar; 54(3):335-44. PubMed ID: 20077416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
    Kai L; Levenson AS
    Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
    Zhou J; Liu B; Geng G; Wu JH
    Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells.
    Iguchi K; Toyama T; Ito T; Shakui T; Usui S; Oyama M; Iinuma M; Hirano K
    J Androl; 2012; 33(6):1208-15. PubMed ID: 22700762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
    Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
    Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
    J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of HO-/MeO-PBDEs on androgen receptor: in vitro investigation and helix 12-involved MD simulation.
    Wang X; Yang H; Hu X; Zhang X; Zhang Q; Jiang H; Shi W; Yu H
    Environ Sci Technol; 2013 Oct; 47(20):11802-9. PubMed ID: 24044724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay.
    Zhao P; Chen SK; Cai YH; Lu X; Li Z; Cheng YK; Zhang C; Hu X; He X; Luo HB
    Biochim Biophys Acta; 2013 Oct; 1834(10):2089-96. PubMed ID: 23871879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of mutant androgen receptors by flutamide.
    Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
    Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations.
    Liu HL; Zhong HY; Song TQ; Li JZ
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28832499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 cells.
    Hsieh TC
    Anticancer Res; 2009 Aug; 29(8):3011-7. PubMed ID: 19661309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.
    Yeh S; Sampson ER; Lee DK; Kim E; Hsu CL; Chen YL; Chang HC; Altuwaijri S; Huang KE; Chang C
    J Formos Med Assoc; 2000 Dec; 99(12):885-94. PubMed ID: 11155740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore.
    Ochiai K; Yonezawa R; Fujii S
    ChemMedChem; 2024 Mar; 19(6):e202400040. PubMed ID: 38291942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.
    Suh JH; Chattopadhyay A; Sieglaff DH; Storer Samaniego C; Cox MB; Webb P
    PLoS One; 2015; 10(9):e0137103. PubMed ID: 26332122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.